Form 8-K

8-K — LISATA THERAPEUTICS, INC.

Accession: 0001140361-26-031028

Filed: 2026-08-04

Period: 2026-08-03

CIK: 0000320017

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Cost Associated with Exit or Disposal Activities

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ef20079399_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (ef20079399_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20079399_8k.htm · Sequence: 1

false0000320017NASDAQ00003200172026-08-032026-08-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

August 3, 2026

Date of Report (date of earliest event reported)

LISATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33650

22-2343568

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

P.O. Box 173 Liberty Corner, NJ 07938

(Address of Principal Executive Offices)(ZipCode)

(908) 842-0100

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.001 per share

LSTA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)

or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to

use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.05

Costs Associated with Exit or Disposal Activities.

On August 3, 2026, the board of directors (the “Board”) of Lisata

Therapeutics, Inc. (the “Company”) approved a reduction in workforce by approximately 72%, effective immediately. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize

shareholder value as the Company plans to pursue strategic options. Affected employees will be offered separation benefits, including severance payments along with temporary healthcare coverage assistance for certain employees. The Company

estimates that it will incur approximately $1.2 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits,

which are expected to be incurred through the quarter ending September 30, 2026. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions,

risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

of Certain Officers.

In connection with the reduction in workforce approved by the Board on August 3, 2026, effective as of August 3, 2026, the employment

of Dr. Kristen K. Buck, M.D., the Company’s Executive Vice President of R&D and Chief Medical Officer was terminated. Pursuant to the Amended and Restated Employment Agreement, dated as of June 10, 2025, between the Company and Dr. Buck (the

“Buck Employment Agreement”), Dr. Buck’s departure from the Company will constitute a termination without Cause (as defined in the Buck Employment Agreement), and, in accordance therewith, subject to Dr. Buck executing a release in favor of the

Company, Dr. Buck is contractually entitled to receive an amount equal to 12 months of her base salary and target bonus compensation and the Company shall pay COBRA premiums for Dr. Buck and her covered dependents for a period of up to 12 months.

In addition, on August 3, 2026, the Board approved a cash retention bonus to James Nisco, the Company’s Senior Vice President, Finance

and Treasury and Chief Accounting Officer, in the amount of $200,000. The cash bonus is payable within thirty (30) days of, and subject to continued employment with the Company through, December 31, 2026; provided that if the applicable executive’s

employment is terminated by the Company without “Cause”, then the retention bonus shall be payable within thirty (30) days of the executive’s execution and non-revocation of a release of claims. The foregoing description is qualified in its

entirety by reference to the form of Retention Bonus Letter Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 8.01.

Other Events.

On July 31, 2026, the Company commenced an action in the Court of Chancery of the State of Delaware suing Kuva Labs Inc. (“Kuva Labs”)

and its wholly-owned subsidiary Kuva Acquisition Corp. over their breach of the Agreement and Plan of Merger, dated as of March 6, 2026, among the Company, Kuva Labs and Kuva Acquisition Corp. (as amended, the “Merger Agreement”). Among other things,

the Company is seeking damages for the benefits its stockholders expected in connection with the transaction.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:

Exhibit

No.

Description

10.1

Retention Bonus Letter Agreement, dated as of August 3, 2026, between the Company and James Nisco.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

LISATA THERAPEUTICS, INC.

By:

/s/ David J. Mazzo

Name: David J. Mazzo, PhD

Title: President and Chief Executive Officer

Dated: August 3, 2026

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: ef20079399_ex10-1.htm · Sequence: 2

Exhibit 10.1

James Nisco

Re: Retention Bonus Opportunity

Dear James:

We are pleased to inform you that, in recognition of your contributions to Lisata Therapeutics, Inc. (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and

conditions:

Eligibility for Retention Bonus. Subject to satisfaction of the conditions set forth below, you will be eligible to be

paid a Retention Bonus in the gross amount of $200,000, less applicable deductions and withholdings, payable in a lump sum to be made within thirty (30) days of the effective date of the Release (as defined below), subject to the terms of

Section 2(b). The “Retention Date” means December 31, 2026.

Conditions to Payment. In order to receive the Retention Bonus, all of

the following conditions must be satisfied:

(a)

You must remain employed by the Company or its subsidiaries in good standing and comply with the terms set forth in this letter through the Retention Date and not have provided notice of your

intention to resign; provided that if you are terminated by the Company without Cause (as defined below) prior to the Retention Date, you shall be eligible for the Retention Bonus which shall be paid within thirty (30) days of the effective

date of the Release (as defined below) subject to the terms of Section 2(b); and

(b)

You must execute and not revoke a release of claims through the Retention Date or, if earlier, your termination of employment without Cause, in favor of the Company and its affiliates in such form

as is presented by the Company (the “Release”). If the applicable review or revocation period for the Release crosses tax years, payment of the Retention Bonus will not be made

until the first regularly scheduled payroll date in the second tax year.

(c)

“Cause” means (as determined in good faith by the Company): (i) your refusal to comply with direct instructions of the Company that are

reasonable and consistent with your duties to the Company and/or its subsidiaries and with relevant requirements of applicable law, which noncompliance, to the extent curable, you fail to cure within ten (10) days following receipt of

written notice from the Company; (ii) you engage in dishonest or willful misconduct which has or is reasonably expected to have a material and adverse effect on the Company, any of its subsidiaries or any of their respective affiliates;

(iii) you perpetrate a fraud, theft, embezzlement or misappropriation against or affecting the Company, any of its subsidiaries or any of their respective affiliates or any customer, client, agent, creditor, equity holder or employee of

the Company, any of its subsidiaries or any of their respective affiliates; (iv) you breach any material obligation that you owe to the Company, any of its subsidiaries or any of their respective affiliates, which breach, to the extent

curable, you fail to cure ten (10) days following receipt of written notice thereof from the Company; (v) you are convicted of, enter a plea of guilty or nolo contendere or have otherwise admitted to the commission of a felony or

indictable offence; (vi) you violate any law or regulation applicable to the Company, any of its subsidiaries, or any of their respective affiliates or breach any of your duties to the Company, any of its subsidiaries or any of their

respective affiliates; or (vii) you fail to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, engages in the willful

destruction of or fails to preserve documents or other materials known to be relevant to such investigation or induces others to fail to cooperate or to produce documents or other materials in connection with such investigation.

Termination of Employment. If your employment with the Company and its

subsidiaries terminates for any reason prior to the Retention Date other than a termination without Cause (or any other condition set forth in paragraph 2 above is not satisfied), your right to payment of the Retention Bonus will be

forfeited in its entirety.

Tax Withholding. Payment of the Retention Bonus will be subject to

applicable federal, state and local tax deductions and withholding.

Effect on Other Benefits. You acknowledge that payment of the Retention

Bonus is not part of normal or expected compensation for purposes of calculating or paying any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, matching

contributions or similar payments. For the avoidance of doubt, payment of the Retention Bonus shall, in each case, have no effect on any benefits derived from your Separation Benefits Agreement, executed by and between you and the Company

on June 10, 2025.

Assignment. The obligation to pay the Retention Bonus is solely that of

the Company, provided that the Company may assign its obligations to any affiliate or entity that succeeds to the Company’s business. You may not assign your right to receive the Retention Bonus.

No Right to Continued Employment. The grant of this Retention Bonus

opportunity does not give you any right to continue your employment relationship with the Company or its subsidiaries, and you shall remain subject to discharge to the same extent as if this opportunity were not granted to you.

Confidentiality. You understand that the matters described in this

letter are confidential, and you agree that you will not disclose or discuss the terms of this letter with any person or entity (other than your immediate family, legal professional, or tax professional), except as required by applicable

law.

Governing Law; JURY WAIVER. Any dispute arising out of or relating to

this letter shall be decided by applying the laws of the State of New York without regard to conflicts of law principles. Each party acknowledges and

agrees that any controversy that may arise under this letter is likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right to a trial by jury in connection with

any dispute arising out of or relating to this letter.

10.

Section 409A Compliance. This letter is intended to comply with Section

409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), or an exemption thereunder, and shall be construed and administered in accordance with such intent.

Notwithstanding any other provision of this letter, payments provided hereunder may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this letter that may be excluded

from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. Notwithstanding the foregoing, the Company makes no

representations that the payments and benefits provided under this letter comply with Section 409A, and in no event shall the Company or any of its affiliates be liable for all or any portion of any taxes, penalties, interest or other

expenses that may be incurred by you on account of non-compliance with Section 409A.

11.

Entire Agreement. This letter contains the entire agreement between you

and the Company with respect to the subject matter hereof and supersedes any prior understandings or agreements, whether written or oral, between you and the Company concerning the Retention Bonus. Notwithstanding the foregoing, nothing

in this letter shall supersede, limit or otherwise affect any restrictive covenant, confidentiality, non-competition, non-solicitation, invention assignment or similar obligations you may have to the Company, any of its subsidiaries or

any of their respective affiliates under any other agreement.

We hope that this arrangement encourages your continued commitment to the Company. Please acknowledge your agreement to the terms

of this letter by countersigning it in the space below and returning it to me.

[Signature page on following page]

Sincerely,

Lisata Therapeutics, Inc.

By:

/s/ David J. Mazzo, Ph.D.

Name: David J. Mazzo, Ph.D.

Title: Chief Executive Officer

/s/ James Nisco

James Nisco

Date: 8/3/2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 03, 2026

Entity File Number

001-33650

Entity Registrant Name

LISATA THERAPEUTICS, INC.

Entity Central Index Key

0000320017

Entity Incorporation, State or Country Code

Entity Tax Identification Number

22-2343568

Entity Address, Address Line One

P.O. Box 173

Entity Address, City or Town

Liberty Corner

Entity Address, State or Province

Entity Address, Postal Zip Code

07938

City Area Code

908

Local Phone Number

842-0100

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

LSTA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration